Sign in
Taking people in United StatesNo phase

Brain stimulation and meditation to support attention in older adults with mild cognitive impairment

Tests meditation and gentle brain stimulation on attention in healthy and mildly impaired adults.

Key facts

Who runs it
University of Texas at Austin
Where
Austin and Georgetown, United StatesSee the 2 sites
Trial code
Registry title
Enhancing Attention in Elderly Using a Brain-Computer-Interface
Status
Recruiting
People taking part
100 people, planned
Started
1 Jul 2026
Expected to end
1 Feb 2029
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • transcranial electrical stimulation
  • Mindfulness Meditation
Record updated
27 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy younger adults and older adults, including older adults with mild cognitive impairment (MCI). It tests meditation and mild brain stimulation with an EEG-based brain-computer interface.

Age
18 Years to 90 Years
Sex
All sexes can join.
Disease stage
Older adults must not have a current diagnosis of dementia. Younger adults must be in good general health, with no history of brain or mental illness.

Main reasons for not taking part

  • Brain or mental illness that makes brain stimulation (tACS) unsafe, such as epilepsy, seizures, brain damage, fainting, bipolar disorder, schizophrenia or current substance use disorder
  • Pacemaker (older adults)
  • Medicines that affect seizure risk, such as stimulant medication or high dose bupropion
  • Scalp problems that block EEG or stimulation, such as skin infection, wounds or dermatitis
  • Diagnosis of dementia, or not able to give informed consent

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Younger adults:
  • Good general health
  • Normal or corrected vision
  • no history of neurological/psychiatric disease
  • ability to read and understand English
  • ability to understand information and ability to give a free and informed consent; Older adults:
  • Normal or corrected vision
  • Self-reports no current diagnosis of dementia
  • Ability to provide written/electronic, informed consent

Who cannot take part

  • Neurological or psychiatric diseases that could be contraindicated for tACS (e.g., personal history of epilepsy/seizure brain damage, history of fainting, bipolar disorder, schizophrenia, current substance use disorder, etc.)
  • Medications that elevate seizure threshold (e.g., stimulant medication, high dose bupropion)
  • Factors hindering EEG acquisition and tACS delivery (e.g., skin infection, wounds, dermatitis, inability to access the scalp of the participant); Older Adults:
  • Neurological or psychiatric diseases that could be contraindicated for tACS (e.g., personal history of epilepsy/seizure brain damage, pacemakers, history of fainting, bipolar disorder, schizophrenia, current substance use disorder, etc.)
  • Medications that elevate seizure threshold (e.g., stimulant medication, high dose bupropion)
  • Factors hindering EEG acquisition and tACS delivery (e.g., skin infection, wounds, dermatitis, inability to access the scalp of the participant)
  • Diagnosis of dementia
  • Younger Adults:
  • Do not have the capacity to provide informed consent

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

This trial is currently available in United States.

  • The University of Texas at AustinAustin, United StatesContact: Jose del R. Millan, PhDTaking people
  • Sun CityGeorgetown, United StatesContact: Khushi ThoratTaking people

About the trial

What the trial wants to find out

Cognitive reserve refers to the brain's ability to maintain cognitive performance despite age-related changes or neuropathology. Enhancing cognitive reserve is thought to delay cognitive decline and improve functional outcomes in aging and neurodegenerative conditions. Attention and memory-related neural processes are considered key contributors to cognitive reserve, yet it remains unclear whether these neural markers can be deliberately strengthened through targeted training and non-invasive interventions.

Read full original descriptionShow less

The goal of this clinical study is to investigate whether mindfulness-based meditation and non-invasive brain stimulation can enhance neural markers of attention and memory that serve as proxies for cognitive reserve in cognitively healthy adults and older adults diagnosed with mild cognitive impairment (MCI). Investigators hypothesize that strengthening these neural markers will lead to measurable improvements in cognitive reserve-related functions in both healthy aging and MCI populations.

This study further hypothesizes that neural markers of attention can be selectively enhanced using an electroencephalography (EEG)-based brain-computer interface (BCI) combined with non-invasive interventions such as mindfulness-based relaxation or neuromodulation. During the study, participants will perform a computerized memory task while their EEG signals are recorded in real time. A BCI will analyze these signals to decode the presence or absence of the P300 event-related potential, a well-established neural marker of attentional control and cognitive resource allocation. Real-time feedback and intervention will be used to modulate these neural processes with the goal of promoting adaptive changes in attention-related brain activity.

By integrating EEG-based decoding, behavioral training, and non-invasive interventions, this study aims to determine whether targeted modulation of attention-related neural activity can support cognitive reserve in aging and mild cognitive impairment.

The 4 groups in the trial

  • Behavior-based Attention control with MeditationExisting treatment, for comparison

    Subjects complete an nback task after a meditation intervention in which ground truth visual feedback is provided at the end of each run.

    Treatment: Mindfulness Meditation

  • Behavior-based Attention control with Open-Loop tACSExisting treatment, for comparison

    Subjects complete an nback task after a tACS intervention in which ground truth visual feedback is provided at the end of each run.

    Treatment: transcranial electrical stimulation

  • EEG-based Attention Control and MeditationTreatment being tested

    Subjects complete an nback task in which EEG-based visual feedback is provided after each trial

    Treatment: Mindfulness Meditation

  • EEG-Based Attention Control and Open-Loop tACSTreatment being tested

    Subjects complete an nback task in which EEG-based visual feedback is provided after each trial

    Treatment: transcranial electrical stimulation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Building Cognitive Reserve Through Brain-Computer-Interfaces
Plain-language title
Brain stimulation and meditation to support attention in older adults with mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07441122, who can take part
Record updated
27 July 2026